Menu

Physician Editorial

About Physician Editorial

http://physicianeditorial.com

Posts by Physician Editorial:

Sanofi and Regeneron Announce UnitedHealth Group Selects Praluent® (alirocumab) Injection for Preferred Access

,

Praluent® is the only PCSK9 inhibitor preferred across UnitedHealth Group formularies, including OptumRx and UnitedHealthcare Commercial, Medicare, and Managed Medicaid formularies BRIDGEWATER, N.J. and TARRYTOWN, N.Y., Dec. 11, 2015 /PRNewswire/ — Sanofi and Regeneron Pharmaceuticals, Inc. today announced that UnitedHealth Group will provide preferred access to Praluent® (alirocumab) Injection through OptumRx and UnitedHealthcare for Commercial, […]

300 million child-friendly antimalarial treatments supplied without profit by Novartis

, , ,

Coartem® Dispersible*, the first WHO prequalified[1] pediatric antimalarial treatment, has become the standard of care in over 30 malaria-endemic countries Since 2009, Novartis has supplied 300 million Coartem® Dispersible treatments without profit, mostly to the public sector, to treat children suffering from malaria Together with other innovations, Coartem® Dispersible contributed to reduce the malaria death […]

Pivotal Phase II study showed nearly 80 percent of people with hard-to-treat type of chronic lymphocytic leukaemia responded to investigational medicine venetoclax

, , , ,

Regulatory applications for venetoclax have been submitted to the U.S. Food and Drug Administration and European Medicines Agency Additional results in previously treated chronic lymphocytic leukaemia from a separate Phase Ib study published online today in New England Journal of Medicine Basel, 7 December 2015 – Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new, […]

Interview: Dr. Terra Caudill, Psychiatrist

Name: Terra Caudill, MD, MS Specialty: Psychiatry Location (City, State): West Palm Beach, FL Website: WestPalmBeachPsychiatry.com 1) What would you like other physicians to know about your specialty? There is a shortage of psychiatrists across the country. If you don’t have access to a psychiatrist, consider using telepsychiatry to have access to patient treatment options that you need. […]

Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia

, ,

Once-Daily, Oral Product Candidate Showed Efficacy Equivalent to Olanzapine With Clinically Meaningful and Statistically Significant Lower Weight Gain in 300-Patient Study Company Plans to Initiate Pivotal Development Program in 2015 DUBLIN–(BUSINESS WIRE)–Jan. 7, 2015– Alkermes plc (NASDAQ: ALKS) today announced positive topline results from the 12-week, randomized, double-blind, active-controlled, dose-ranging stage of a phase 2 […]

Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder

, ,

Safety and Tolerability Profile of ALKS 5461 Confirmed in FORWARD-1 Study, a Supportive Study in the FORWARD Phase 3 Pivotal Program Dosing Regimen Confirmed; Efficacy Data Showed Statistically Significant Improvements in Depression Scores Beginning at Week One and Continuing Through Eight-Week Treatment Period DUBLIN–(BUSINESS WIRE)–Jan. 6, 2015– Alkermes plc (NASDAQ: ALKS) today announced topline results […]

Soliris® (eculizumab) Granted Orphan Drug Designation in Japan for the Treatment of Patients with Myasthenia Gravis

,

CHESHIRE, Conn. December 10, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that Soliris® (eculizumab) has been granted orphan drug designation (ODD) by Japan’s Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myasthenia gravis (MG), a rare, debilitating neurologic disorder. In patients with MG, uncontrolled complement activation due to antibodies […]

New Data Presented at ASH Annual Meeting Enhance Clinical Knowledge of aHUS and PNH and Underscore the Effectiveness of Soliris® (eculizumab) Treatment

,

New Analyses Report Clinical Benefits of Ongoing Soliris Therapy in Children and Adults with aHUS With or Without Identified Genetic Mutations Observational Data Highlight Importance of High Sensitivity Flow Cytometry to Enable Reliable Detection of PNH Cells CHESHIRE, Conn. December 8, 2014 –(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that researchers presented data that continue […]

RainDance Forms Hematologic Oncology Consortium to Develop Assays for Liquid Biopsy Research of Myeloid Disorders

,

HemOnc experts validate unmet need and performance of new ThunderBolts Myeloid NGS Panel at ASH 2014 BILLERICA, Mass. — December 5, 2014 — RainDance Technologies, Inc., a genomics tools company simplifying the analysis of complex genetic diseases, today announced the formation of the RainDance HemOnc Consortium, composed of a select group of hematologic clinical research […]

Sequenta Launches New Online Results Portal for Physicians

,

Secure, real-time access to ClonoSIGHT™ test results, order status, patient MRD trends SOUTH SAN FRANCISCO, Calif. DECEMBER 4, 2014 – Sequenta, Inc. today announced the launch of its new physician portal, the ClonoSIGHT Secure Portal (https://results.clonosight.com). The HIPAA-compliant online portal enables physicians to more effectively integrate the ClonoSIGHT process, an ultra-sensitive, next-generation sequencing-based technology for […]

«‹ 66 67 68 69›»